BioCentury | Oct 10, 2011
Clinical News

HVJ-E: Phase I/II start

...trial evaluate intratumoral and subcutaneous injections of HVJ-E in 12 CRPC patients. In 2009, AnGes' GenomIdea Inc....
BioCentury | Jun 27, 2011
Company News

AnGes, TSD Japan deal

...AnGes' GenomIdea Inc. subsidiary and TSD will jointly search for new partners to aid in the global...
...in the global development and commercialization of cancer candidate GEN0101 / TSD-0014 (HJV-E). In 2009, GenomIdea...
BioCentury | Nov 22, 2010
Company News

AnGes, Vical deal

...Vical and AnGes' GenomIdea Inc. subsidiary partnered to develop a DNA vaccine using Vical's Vaxfectin adjuvant against...
...develop a DNA vaccine using Vical's Vaxfectin adjuvant against pandemic influenza for use in livestock. GenomIdea...
...the resulting livestock vaccine. Funding will be provided by the Okinawa Industry Promotion Public Corp. GenomIdea's...
Items per page:
1 - 3 of 3
BioCentury | Oct 10, 2011
Clinical News

HVJ-E: Phase I/II start

...trial evaluate intratumoral and subcutaneous injections of HVJ-E in 12 CRPC patients. In 2009, AnGes' GenomIdea Inc....
BioCentury | Jun 27, 2011
Company News

AnGes, TSD Japan deal

...AnGes' GenomIdea Inc. subsidiary and TSD will jointly search for new partners to aid in the global...
...in the global development and commercialization of cancer candidate GEN0101 / TSD-0014 (HJV-E). In 2009, GenomIdea...
BioCentury | Nov 22, 2010
Company News

AnGes, Vical deal

...Vical and AnGes' GenomIdea Inc. subsidiary partnered to develop a DNA vaccine using Vical's Vaxfectin adjuvant against...
...develop a DNA vaccine using Vical's Vaxfectin adjuvant against pandemic influenza for use in livestock. GenomIdea...
...the resulting livestock vaccine. Funding will be provided by the Okinawa Industry Promotion Public Corp. GenomIdea's...
Items per page:
1 - 3 of 3